Fortress Biotech, Inc. Operating Lease Liability
Fortress Biotech, Inc. (FBIO) had Operating Lease Liability of $13.71 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-13
- 2026-06-30: Operating Lease, Liability $13.71M.
- 2026-03-31: Operating Lease, Liability $14.25M.
- 2025-12-31: Operating Lease, Liability $14.80M.
- 2025-09-30: Operating Lease, Liability $14.89M.
| Period end | Operating Lease, Liability | Operating Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $13.71M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $14.25M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $14.80M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $14.89M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $15.44M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $15.98M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $17.37M 10-K · filed 2025-03-31 | |
| 2024-09-30 | $17.81M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $18.41M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $20.22M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $20.80M 10-K · filed 2024-03-28 | |
| 2023-09-30 | $21.36M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $21.83M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $23.54M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $24.02M 10-K · filed 2023-03-31 | |
| 2022-09-30 | $23.75M 10-Q · filed 2022-11-14 | |
| 2021-12-31 | $23.09M 10-K · filed 2022-03-28 | |
| 2020-12-31 | $23.10M 10-K · filed 2022-03-28 | $24.74M 10-K · filed 2021-03-31 |
| 2020-09-30 | $24.55M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $25.00M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $25.44M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $24.70M 10-K/A · filed 2021-04-09 | $25.50M 10-K · filed 2020-03-16 |
| 2019-09-30 | $25.91M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $26.14M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $26.47M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |